These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38913537)

  • 1. Bidirectional crosstalk between bone and muscle: the role of RANKL pathway in osteosarcopenia.
    Jang SY; Choi KM
    J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38913537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.
    Boulanger Piette A; Hamoudi D; Marcadet L; Morin F; Argaw A; Ward L; Frenette J
    Curr Osteoporos Rep; 2018 Oct; 16(5):541-553. PubMed ID: 30225627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases.
    Colaianni G; Storlino G; Sanesi L; Colucci S; Grano M
    Curr Osteoporos Rep; 2020 Aug; 18(4):401-407. PubMed ID: 32514668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle-bone crosstalk via endocrine signals and potential targets for osteosarcopenia-related fracture.
    Sheng R; Cao M; Song M; Wang M; Zhang Y; Shi L; Xie T; Li Y; Wang J; Rui Y
    J Orthop Translat; 2023 Nov; 43():36-46. PubMed ID: 38021216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P; Isaia G; Isaia GC
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice.
    Hamoudi D; Marcadet L; Piette Boulanger A; Yagita H; Bouredji Z; Argaw A; Frenette J
    Hum Mol Genet; 2019 Sep; 28(18):3101-3112. PubMed ID: 31179501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on the effects of receptor activator of nuclear factor-B ligand inhibition on bone mass and muscle strength.
    Hwang JS; Lien AS; Jiang YD
    J Diabetes Investig; 2020 Mar; 11(2):287-289. PubMed ID: 31633306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle, Bone, and Fat Crosstalk: the Biological Role of Myokines, Osteokines, and Adipokines.
    Kirk B; Feehan J; Lombardi G; Duque G
    Curr Osteoporos Rep; 2020 Aug; 18(4):388-400. PubMed ID: 32529456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.
    Woźniczka M; Błaszczak-Świątkiewicz K
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL/RANK-beyond bones.
    Hanada R; Hanada T; Sigl V; Schramek D; Penninger JM
    J Mol Med (Berl); 2011 Jul; 89(7):647-56. PubMed ID: 21445556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL Mediates Muscle Atrophy and Dysfunction in a Cigarette Smoke-induced Model of Chronic Obstructive Pulmonary Disease.
    Xiong J; Le Y; Rao Y; Zhou L; Hu Y; Guo S; Sun Y
    Am J Respir Cell Mol Biol; 2021 May; 64(5):617-628. PubMed ID: 33689672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical guide to the pathophysiology, diagnosis and treatment of osteosarcopenia.
    Kirk B; Miller S; Zanker J; Duque G
    Maturitas; 2020 Oct; 140():27-33. PubMed ID: 32972632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoimmunology: memorandum for rheumatologists.
    Zhao L; Huang L; Zhang X
    Sci China Life Sci; 2016 Dec; 59(12):1241-1258. PubMed ID: 27650950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc supplements and bone health: The role of the RANKL-RANK axis as a therapeutic target.
    Amin N; Clark CCT; Taghizadeh M; Djafarnejad S
    J Trace Elem Med Biol; 2020 Jan; 57():126417. PubMed ID: 31653549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL biology.
    Takegahara N; Kim H; Choi Y
    Bone; 2022 Jun; 159():116353. PubMed ID: 35181574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcopenia, osteoporosis and frailty.
    Gielen E; Dupont J; Dejaeger M; Laurent MR
    Metabolism; 2023 Aug; 145():155638. PubMed ID: 37348597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.